Sector concallsPharmaceuticals & Healthcare
- Advanced Enzyme Technologies Limited
- Alkem Laboratories Limited
- Dishman Carbogen Amcis Limited
- Entero Healthcare Solutions Limited
- Fischer Medical Ventures Ltd
- Fortis Healthcare Limited
- Gaudium IVF and Women Health Limited
- Granules India Limited
- Gufic Biosciences Limited
- Gujarat Themis Biosyn Limited
- Health X Platform Limited
- Healthcare Global Enterprises Limited
- Hexagon Nutrition Limited
- Ind-Swift Laboratories Limited
- IOL Chemicals & Pharmaceuticals Ltd
- IPCA Laboratories Limited
- Jeena Sikho Lifecare Limited
- Krsnaa Diagnostics Limited
- Laxmi Dental Limited
- Manipal Health Enterprises Limited
- Marksans Pharma Limited
- Max Healthcare Institute Limited
- Medi Assist Healthcare Services Limited
- Molbio Diagnostics Limited
- Natco Pharma Limited
- Nephrocare Health Services Limited
- Orchid Pharma Limited
- Poly Medicure Limited
- QMS Medical Allied Services Limited
- Rubicon Research Limited
- Sai Parenterals Limited
- Shaily Engineering Plastics Limited
- Shalby Limited
- Supriya Lifescience Limited
- Suraksha Diagnostic Limited
- Symbiotec Pharmalab Limited
- Tarsons Products Limited
- Viyash Scientific Limited
- Yatharth Hospital & Trauma Care Services Limited
- Zota Health Care LImited
- Zydus Lifesciences Limited
HCG has scheduled its Q2 FY27 earnings call for November 6, 2026 to discuss results to be declared on November 5, 2026, with no financials disclosed in this intimation.
Management said Granules returned to growth in FY26 and is shifting from building manufacturing and R&D capabilities to scaling four growth engines of controlled substances, complex generics with first-to-file opportunities, oncology and peptide CDMO.
- Gross margin
- 65 percentabout 15 percentage points
- EBITDA margin
- 22 percentthree percentage points
Q1 FY27 was driven by the established steroid API business while consolidated profit was reduced by operating costs and depreciation from the new biotech CDMO and complex injectables facilities awaiting first revenues in the next 6 to 12 months.
- Consolidated revenue Q1 FY27
- ₹218 Crgrowth of 7% YoY
- API revenue Q1 FY27
- ₹215 Crgrowth of 6% YoY
Q1 FY27 was led by the Truenat point-of-care molecular platform with recurring kit sales driving revenue, while management pointed to TB scale-up, HPV rollout, and U.S. and Europe expansion as next growth drivers.
- Revenue from operations (Q1 FY27)
- ₹408 Cr
- EBITDA (Q1 FY27)
- ₹104 Cr
Fischer Medical Ventures used its September 7, 2026 investor call to present its AI-enabled imaging platform, proprietary technology stack and leadership team, without disclosing quarterly financial results.
Delhi High Court ordered a court-supervised forensic audit into erstwhile promoter share dissipation, IHH's acquisition of control and use of funds for RHT assets, which Fortis and IHH say leaves operations, capex, bed expansion and M&A unrestricted and is expected to have no material adverse outcome.
Quarterly revenue improved 15% year-over-year and EBITDA grew on better gross margins, but the core cephalosporin business continues to face intense industry pricing pressure.
- Revenue from Operations
- ₹304 Crapprox. 15%
- Combined Gross Margin
- 33%approx. 3% points
Manipal Hospitals delivered strong growth in its first quarter as a public company, driven by patient demand, high-acuity specialty care, and the integration of Sahyadri Hospitals.
- Revenue from Operations
- ₹3,091 Cr38.1%
- EBITDA
- ₹749 Cr26.4%
Max Healthcare posted strong revenue growth and continued its capacity expansion while embarking on a new medical education business.
- Network Gross Revenue
- ₹2,982 Cr16% YoY, 12% QoQ
- Network Operating EBITDA
- ₹704 Cr15% YoY, 3% QoQ
The company delivered strong financial performance driven by its transformation into a focused FDF manufacturer, with new CDMO partnerships commercialized and sharp margin expansion.
- Operating Income
- ₹186.08 Cr21.16%
- Operating EBITDA
- ₹33.32 Cr2.85x
Zydus Lifesciences started FY27 with strong double-digit growth across all key businesses, driven by branded formulations in India, international markets, and strategic advancements in specialty and innovation.
- Consolidated Revenue
- ₹8,020 Cr22%
- EBITDA Margin
- 24.1%
Advanced Enzyme Technologies reported a muted quarter impacted by sales reversals and global disruptions, but management maintains confidence in achieving double-digit annual growth.
- Revenue
- ₹189.8 Cr2% YoY
- EBITDA
- ₹51 Cr-10% YoY
Gufic Biosciences delivered strong Q1 growth driven by improved margins from its new Indore plant, progress on complex injectable capabilities, and a strategic shift in its international business model.
- Total Revenue from Operations
- ₹260.8 Crvs ₹226.9 Cr YoY
- EBITDA
- ₹47.2 Crvs ₹33.2 Cr YoY
Despite a soft revenue quarter, management is focused on sales force expansion, tech transfers to India, and a significant debt refinancing to improve margins, projecting an optimistic future.
- Income from Operations
- ₹677.6 Cr-4%
- EBITDA
- ₹60 Cr
Q1 FY27 saw strong revenue and profit growth driven by scaling service business (Patient Support Programs) and strategic investments beginning to yield results.
- Consolidated Revenue
- ₹56.9 Cr+22% YoY growth
- EBITDA
- ₹8.3 Cr+27% YoY growth
Strong profit growth driven by a bumper flu season in the associate Adcock Ingram and double-digit growth in the base business.
- Consolidated Revenue
- ₹794.4 Cr
- EBITDA Margin
- 30.9%
Ipca delivered robust 21% revenue growth and significantly improved EBITDA margins by 4.49 percentage points to 22.88%, revising its full-year revenue growth guidance upward.
- Consolidated Revenue
- ₹2,788 Cr21%
- Consolidated EBITDA Margin
- 22.88%4.49%
Revenue growth was driven by international sales and branded formulations in India, but net profit declined sharply due to tax impacts and ongoing investments in new, loss-making CDMO and MedTech businesses.
- Revenue from Operations
- ₹3,740 Crclose to 11% YoY growth
- India Sales
- ₹2,497 Cr+10.3% YoY growth
The company began FY27 with strong momentum, driven by retail network expansion and increased consumer footfalls, while planning a moderated pace of store openings to focus on productivity.
- Revenue from Operations
- ₹173.6 Cr67.6% Y-O-Y
- Gross Margin
- 61.96%
The quarter was driven by the transition of the large Rajasthan PPP project from infrastructure build-out to revenue generation, strong retail growth, and a new project win in Himachal Pradesh.
- Revenue from Operations
- ₹235.5 Cr22%
- EBITDA
- ₹58.8 Cr
Gaudium IVF's Q1 focused on investing ahead of its expansion roadmap, absorbing higher costs for marketing its new AI tools and new hub development while maintaining confidence in achieving its full-year growth targets.
- Revenue from Operations (Q1 FY27)
- ₹19.4 Cr9.1%
- EBITDA
- ₹2.4 Cr-52.96%
Rubicon delivered strong top-line and bottom-line growth, raised EBITDA guidance, and advanced its strategic manufacturing footprint with a new U.S. site.
- Revenue
- ₹534.3 Cr52%
- EBITDA
- ₹129.1 Cr63.2%
Revenue grew 31% year-on-year, but EBITDA margin contracted to 25% due to temporary water scarcity and one-off solar policy costs, though management remains confident in its full-year revenue and margin guidance.
- Revenue
- ₹190 Cr31%
- EBITDA
- ₹47 Cr-8.1%
The company started FY27 with strong revenue growth of 43.2% and has a robust order book, focusing on expanding its branded business and mitigating margin pressures.
- Consolidated Revenue
- ₹104.3 Cr43.2%
- EBITDA
- ₹11.8 Cr17.3%
Strong Q1 growth driven by successful diversification beyond ibuprofen, with non-ibu APIs contributing 43% of pharma revenue and a 60.7% EBITDA increase.
- Revenue
- ₹756 Cr37%
- EBITDA
- ₹111 Cr60.7%
The company started FY27 with record quarterly revenue, EBITDA, and PAT, driven by strong European growth via acquisitions and organic expansion across all geographies.
- Revenue
- ₹840.8 Cr35.6%
- EBITDA
- ₹213 Cr112.8%
The quarter was about the hospital segment showing steady revenue growth while MedTech delivered strong top-line expansion, but both faced profitability pressure and management is focused on executing levers for margin improvement.
- Consolidated Revenue
- ₹338.6 Cr11.6%
- Consolidated EBITDA
- ₹49 Cr1%
Suraksha delivered strong financial performance in Q1 with a 40% PAT growth, successful network expansion, and significant progress in its genomics vertical.
- Total Income
- ₹88.7 Cr21%
- EBITDA
- ₹31.5 Cr28%
NephroPlus delivered strong Q1 growth with revenue up 23.7% and continued strategic expansion into new cities and countries, driven by its scalable platform model focused on quality, accessibility, and affordability of dialysis care.
- Revenue
- ₹282 Cr23.7%
- Adjusted EBITDA
- ₹65 Cr30.7%
Laxmi Dental achieved its highest-ever quarterly revenue and profitability, driven by strong growth across its dental lab and aligner solutions businesses.
- Revenue
- ₹74.7 Cr13.9%
- EBITDA
- ₹14.4 Cr20.6%
Viyash delivered strong Q1 growth with improved margins and a strengthened, nearly debt-free balance sheet, positioning it for strategic investments in R&D, manufacturing, and targeted M&A.
- Revenue from Operations
- ₹946 Cr20%
- EBITDA
- ₹205 Cr59%
The quarter was about improved margins on a seasonally lower revenue base and the strategic reallocation of IPO funds to acquire majority stakes in two operating pharmaceutical assets, accelerating entry into complex injectables and R&D.
- Consolidated Total Revenue
- ₹182 Cr
- Gross Profit Margin
- 41.8%370 bps
Yatharth delivered its highest ever quarterly revenue and profits, with 51% revenue growth driven by successful integration and rapid scaling of newer hospitals, while maintaining a focus on premium payer mix and expansion to 5,000 beds.
- Revenue
- ₹392.7 Cr51% year-over-year
- EBITDA
- ₹91.7 Cr39% year-over-year
Tarsons delivered strong 21% revenue growth in Q1 FY27, driven by domestic recovery and export rebound, but profitability was pressured by sharply higher raw material costs and new facility ramp-up expenses.
- Consolidated Revenue
- ₹110 Cr21% Y-o-Y
- Standalone Revenue
- ₹86.1 Cr21% Y-o-Y
Health X delivered its highest-ever quarterly revenue, with strong growth in RetailerShakti and SastaSundar, as previous investments in geography, fulfillment, and the JITO private label begin to translate into momentum.
- Revenue from Operations
- ₹440 Cr58% Y-o-Y
- Gross Margin
- 7.8%
Healthcare, now the largest segment with 85% revenue growth, drove overall performance amid a challenging global environment and softer Consumer demand.
- Revenue
- ₹281 Cr14%
- EBITDA
- ₹83 Cr18%
PolyMed reported a strong start to its 'PolyMed 3.0 Ascent' phase with Q1 FY27 delivering revenue and EBITDA growth above guidance, driven by strategic acquisitions and a recovery in core segments.
- Consolidated Revenue
- ₹525 Cr30.3%
- Consolidated Operating EBITDA
- ₹126.7 Cr17.7%
Medi Assist delivered strong overall revenue growth, advanced its three strategic growth engines—India TPA, technology platform, and international expansion—and is progressing on margin recovery post-acquisition integration.
- Total Income
- ₹247 Cr24.9% YoY
- Operating Revenue
- ₹236.5 Cr24.1% YoY
Jeena Sikho reported strong growth driven by its integrated preventive healthcare model, focusing on a 30% YoY revenue growth target and expansion into luxury wellness and OTC products.
- Revenue from Operations
- ₹224 Cr29% YoY
- EBITDA
- ₹92 Cr17% YoY
The company is in a transformational phase, focusing on becoming a fermentation-based CDMO through major acquisitions and capacity expansion, while posting strong quarterly growth.
- Revenue from Operations
- ₹43.8 Cr22.1%
- EBITDA
- ₹20.8 Cr49.4%
Entero delivered a strong start to FY27, exceeding full-year margin guidance in Q1 with 38.2% revenue growth and a 143 bps expansion in EBITDA margin to 5%, driven by scale, mix, and deliberate portfolio actions.
- Revenue
- ₹1,940 Cr38.2% YoY
- EBITDA Margin
- 5%143 bps YoY